Physician profile
Reuben L Sutter
NPI 1962463877
$4,853.14
in general payments reported to CMS, 2019-2025
18 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $738 · 2021: $1,672 · 2022: $483 · 2023: $322 · 2024: $408 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.32 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,449.71 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Otsuka America Pharmaceutical, INC. | $734.28 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $409.81 | 2020-2025 | Caplyta |
| Alkermes, INC. | $293.20 | 2019-2023 | Aristada, Vivitrol, Lybalvi |
| Janssen Pharmaceuticals, INC | $260.14 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $238.22 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $96.69 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $91.56 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $65.73 | 2024 | Cobenfy |
| Abbvie INC. | $38.02 | 2021 | |
| Axsome Therapeutics, INC. | $32.28 | 2023-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $31.74 | 2020 | |
| Neuronetics, INC. | $27.99 | 2023 | Neurostar Tms Therapy System |
| Allergan, INC. | $21.90 | 2020 | |
| Gilead Sciences, INC. | $18.76 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $17.29 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $13.38 | 2019 | |
| Merck Sharp & Dohme LLC | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Sutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.